Newsletter | July 1, 2022

07.01.22 -- A Model For Success In Cancer Drug Development

 
New Podcast Episode
Featured Articles
Scouting Turbulence For Opportunity
 

With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.

A Network And Pivot Model For Success In Cancer Drug Development
 

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.

Phase 2/3 Service Provider Attributes Gaining In Selection Importance
 

In ISR’s recent CRO Benchmarking study, outsourcers of Phase 2/3 clinical development services were asked to identify attributes that have been rising in importance as CRO selection criteria over the past 12 months.

Web-Exclusive Content
FDA Finds Drug Shortages Are Mostly Caused By Quality Issues
 

New FDA guidance on risk management plans (RMPs) to mitigate the potential for drug shortages recommends an RMP for drugs that treat rare diseases and conditions, drugs with no alternatives, sole source products, products with only one API or manufacturing site available, and drugs made in facilities where an Official Action Indicated has been issued.

Industry Insights
5 Tips For Operationalizing Gene Therapy Studies

Discover tips on operationalizing gene therapy studies in order to optimize site selection and patient recruitment and engagement.

Digital Edition
July 2022 Digital Edition
 

Inside you will find more on:

  • Companies To Watch
  • CEO Corner
  • Global Update
  • Leadership Lessons

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines
 

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.